Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Convergent action on AMR identified as an important area of intervention
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Subscribe To Our Newsletter & Stay Updated
